Tylenol

DEA Rescheduling of Cannabis A Big Win for Patients

Retrieved on: 
Wednesday, May 1, 2024
Tylenol, Codeine, CFP, Associated, News, Hope, NFL, Schedule, Testosterone, Entrepreneurship, Federation, Cannabis, Injury, Press, Patient, War, Schedule 3, DEA, Ketamine, Drug

WASHINGTON, April 30, 2024 /PRNewswire/ -- The Cannabis Freedom Party (CFP) is very pleased to learn of the news from the Associated Press that the U.S. Drug Enforcement Administration will move to reclassify cannabis as a Schedule 3 drug. The CFP sees this reclassification as a major win for the industry and patients.

Key Points: 
  • The CFP sees this reclassification as a major win for the industry and patients.
  • While some may say that descheduling is truly what's needed, today's decision put necessary points on the board for medical cannabis patients across this country," said Ricky Williams, Co-Founder of CFP.
  • According to the DEA, Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence.
  • The rescheduling of cannabis to Schedule 3, this will now open the door for countless other patients who need access to this life saving medicine," said Jim McMahon, Co-Founder of CFP.

Seasonal Affective Disorder: Shedding Light on the Winter Blues with AltaPointe Health

Retrieved on: 
Tuesday, February 27, 2024
SAD, Woman, Mental health, Headache, Serotonin, Ibuprofen, Seasonal affective disorder, Risk, Melatonin, Depression, School, Fatigue, Family, Sunlight, Tylenol, Appetite, Season, Ageing, Sadness, Nursing

MOBILE, Ala., Feb. 26, 2024 /PRNewswire/ -- As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD). SAD is a type of depression that typically occurs when exposure to sunlight is limited.

Key Points: 
  • As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD).
  • MOBILE, Ala., Feb. 26, 2024 /PRNewswire/ -- As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD).
  • "If you have Seasonal Affective Disorder, it can cause you to be depressed up to 40% of the year."
  • Light therapy, which involves exposure to a bright light that mimics natural sunlight, is a commonly prescribed treatment.

Bundle up to spend flexible spending account (FSA) dollars before the December 31 use-it-or-lose-it deadline with 10 exclusive product bundles from FSA Store

Retrieved on: 
Tuesday, December 26, 2023
Sinusitis, Allergy, Pain, Health, Commerce, Neutrogena, Pedialyte, Motion, Tylenol, Aura, Calendar, Acne, FSA, Myalgia, Massage, Travel, Ship, Pressure, Medicine cabinet, Skin, Life

DALLAS, Dec. 26, 2023 /PRNewswire-PRWeb/ -- Giving gifts to loved ones is a highlight of the holiday season, but the end of the year is also an opportunity for shoppers to give themselves the gift of better health while protecting their tax-free healthcare funds. For the millions of flexible spending account (FSA) users who face a December 31 use-it-or-use it deadline, this is the time to manage last-minute spending and avoid forfeiting an average of $300 to a missed deadline. FSA Store® makes it easy and efficient to spend FSA funds by offering exclusive product bundles that allow consumers to find and buy related products that are grouped according to popular themes or needs.

Key Points: 
  • For the millions of flexible spending account (FSA) users who face a December 31 use-it-or-use it deadline, this is the time to manage last-minute spending and avoid forfeiting an average of $300 to a missed deadline.
  • FSA Store ® makes it easy and efficient to spend FSA funds by offering exclusive product bundles that allow consumers to find and buy related products that are grouped according to popular themes or needs.
  • Our exclusive product bundles are the perfect way to spend funds – whether you have $20 or $200 in your FSA – on items that you will use every day.
  • To learn more about the FSA deadline and how to spend funds before Dec. 31, visit FSAstore.com and the FSA Learning Center .

12th Annual MJBizCon Welcomes Thousands of Cannabis Professionals Who Dare to Grow, Innovate, and Inspire into 2024

Retrieved on: 
Wednesday, November 29, 2023
Codeine, Woman, Policy, Hope, Las Vegas Convention Center, Tylenol, Drug

The 12th annual MJBizCon welcomed tens of thousands of cannabis professionals for the $34 billion industry's premier event.

Key Points: 
  • The 12th annual MJBizCon welcomed tens of thousands of cannabis professionals for the $34 billion industry's premier event.
  • MJBizCon is where the game changers, rule breakers, and disruptors unite to connect, innovate and leave their mark on the industry.
  • The annual "State of the Industry and Predictions for 2024'" opened the event this morning.
  • "With the possibility of rescheduling and tax policy change on the horizon, 2024 could be much more prosperous than 2023."

Minneapolis “Good Wins” Advertising Agency Preston Spire Hires Its First-Ever Chief Marketing Officer

Retrieved on: 
Tuesday, October 31, 2023
Digital Marketing, Social Media, Publishing, Public Relations, Investor Relations, Marketing, Content Marketing, Advertising, Communications, Essentia, UnitedHealth Group, Minnesota State Lottery, QuickBooks, Cannes Lions International Festival of Creativity, Webby Awards, Tylenol, Brawny, Multimedia, London International Awards, Growth, Georgia-Pacific, Clio Awards, Kimble, Fallon, Phillips Distilling Company, CMO, South Indian International Movie Awards, Johnson & Johnson, Film industry, Effie Robinson, Ogilvy, Essence

Preston Spire , Minneapolis’ independently owned “Good Wins” agency, has named Victor Kimble as its first Chief Marketing Officer.

Key Points: 
  • Preston Spire , Minneapolis’ independently owned “Good Wins” agency, has named Victor Kimble as its first Chief Marketing Officer.
  • Kimble will be responsible for amplifying the agency’s Good Wins brand to drive agency growth.
  • (Photo: Business Wire)
    Kimble brings significant agency experience, with 13 years in New York at Fallon, Deutsch and Ogilvy.
  • “Victor is at a caliber that will take our agency to the next level,” says Jennifer Spire, Partner and CEO of Preston Spire.

Skyline Corporate Communications Group, LLC President, Scott Powell, Named by Business Insider Magazine as one of the Nation’s Top 18 Public Relations Executives

Retrieved on: 
Wednesday, September 27, 2023
Business, IPO, Wall Street, M3 Communications Group, Inc, PR, Skyline, Tylenol

Utilizing criteria such as clients, influence, and impact -- and including industry professionals who counseled such clients as Tylenol (during its 1982 poisoning scare), E. Jean Carroll, and President Biden himself – Business Insider named the 18 PR executives it believes have demonstrated the most effective track record in managing a diverse range of crisis situations.

Key Points: 
  • New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC, a consulting agency that provides customized corporate communications and strategic investor relations advisory services to publicly traded and pre-IPO companies, today announced that its President, Scott Powell, was named as one of Business Insider’s 18 leading U.S. crisis communications and public relations (“PR”) experts in the United States.
  • Powell, who has nearly 25 years of Wall Street experience and has provided investor and public relations counsel to some 150+ public companies, has been widely published, quoted and interviewed on a variety of investor relations and public relations topics, including crisis communications.
  • Skyline Corporate Communications Group, LLC currently provides numerous public and pre-IPO corporate clients with investor relations, corporate communications, media relations and, of course, crisis communications services.
  • More information about Skyline and the executive team is available on their website at www.skylineccg.com .

Ellen Mellody and Maria Brasco Wurmbach Join KCSA Strategic Communications in Senior Leadership Roles

Retrieved on: 
Wednesday, September 6, 2023
Controlled Substances Act, Drug, White House, Comcast, General Electric, U.S. Department of Defense Strategy for Operating in Cyberspace, HHS, Health, KCSA, Codeine, Politics, Office of Inspector General, U.S. Department of Health and Human Services, Social media, Tylenol, Ground substance, Tech, Schedule, Ellen, DEA, Girls Venture Corps Air Cadets, Philippine Drug Enforcement Agency, The Ellen DeGeneres Show, Cannabis, Principal, Roger Clinton Sr., Emmy Awards, News, White House press corps

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- KCSA Strategic Communications ("KCSA" or the "Firm"), a leading integrated communications firm, announced today an expansion of the senior leadership team within its cannabis and psychedelic practices. Ellen Mellody has joined the Firm as senior vice president of its Public Relations Team and Maria Brasco Wurmbach has joined as senior vice president of its Social Media Team. Both Ms. Mellody and Ms. Brasco Wurmbach previously served in senior leadership roles at MATTIO Communications ("MATTIO").

Key Points: 
  • NEW YORK, Sept. 6, 2023 /PRNewswire/ -- KCSA Strategic Communications ("KCSA" or the "Firm"), a leading integrated communications firm, announced today an expansion of the senior leadership team within its cannabis and psychedelic practices.
  • Ellen Mellody has joined the Firm as senior vice president of its Public Relations Team and Maria Brasco Wurmbach has joined as senior vice president of its Social Media Team.
  • Both Ms. Mellody and Ms. Brasco Wurmbach previously served in senior leadership roles at MATTIO Communications ("MATTIO").
  • "KCSA is bringing on the strongest talent and growing the best strategic communications, investor relations and digital and social media practices across the financial, healthcare, tech, cannabis and psychedelics industries.

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

Retrieved on: 
Wednesday, August 30, 2023
Alvogen, Priority review, Patent, Partnership, Rockefeller Neuroscience Institute, Nociception, Schnitzer, Spinal cord, Drug discovery, Clinical trial, Licensure, DSM-IV codes, United States patent law, Coronavirus Scientific Advisory Board, Medication, NMDA, Research, Brain, Tylenol, CNS, Feinberg School of Medicine, Dark Enlightenment, Data collection, Pain, Thalamus, Nonsteroidal anti-inflammatory drug, Ketamine, DCS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Northwestern University, Food, Pharmaceutical industry, Dietary supplement, Vaccine, Poultry farming, Defense, Anesthesia, File, Chronic pain, Surgery

The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.

Key Points: 
  • The IND application leverages pioneering research on the use of D-cycloserine (a key ingredient of NRX-101) in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain.
  • Chronic pain is estimated to be a $72 billion industry today with the potential to grow to a $120 billion industry by 2033.
  • Dr. Apkarian is the inventor of the patent and a global expert in pain research and has important experience studying DCS in chronic pain.
  • In experimental models and clinical studies, NMDA antagonists have demonstrated attenuation of pain and shown potential to reduce opioid craving.

Back-to-school checklist: Health-E Commerce® shares 10 ways to use flexible spending account (FSA) and health savings account (HSA) funds to prepare for a healthy year

Retrieved on: 
Tuesday, August 29, 2023
Bruise, Arthralgia, Dehydration, Fever, Acne, Tylenol, Inflammation, Book, Back pain, Currency strap, Child, Chemical oxygen demand, OTC, FSA, Health, Sodium, HSA, Bandage, Potassium, Skin, Commerce, Chirp, Nursing, Online shopping, Birth control, Cosmetics, DALLAS, Dinosaur

DALLAS, Aug. 29, 2023 /PRNewswire-PRWeb/ -- The cost of back-to-school has been rising steadily over the last two decades and it's projected that American families will spend an average of $890 to send their kids back to school this year. Households wondering how they can overcome this significant financial burden should be aware of newly released spending tips from Health-E Commerce®, parent brand to FSA Store® and HSA Store®, designed to help Americans enrolled in flexible spending accounts (FSAs) and health savings accounts (HSAs) use their tax-advantaged dollars to counteract the high cost of back-to-school.

Key Points: 
  • According to the experts at Health-E Commerce, these are the Top 10 most popular back-to-school wellness items this year.
  • Staying in front of cold or fever symptoms with effective monitoring is crucial to keeping your child healthy and thriving this school year.
  • Use FSA or HSA funds to experience the soothing vibrations of the Chirp Pro Wheel.
  • To keep making smart money moves with your tax-free dollars all year-round, visit the FSA Store or HSA Store Learning Centers, or use our interactive tax calculator.

Migraine: A common headache disorder that is underdiagnosed and undertreated

Retrieved on: 
Tuesday, August 1, 2023
Steps, Epilepsy, Association, Review, Asthma, Headache, Central nervous system, Depression, Failure, Traffic light, Awareness, Prevalence, Canadian Headache Society, Genetics of migraine headaches, Speech, Disability, Anxiety, Cardiovascular disease, Light, Quality of life, Hypoesthesia, Head, CGRP, Woman, Research, Movement, Blood, Vomiting, Medication, Pain, Man, Paracetamol, Income, Vascular disease, Sound, Nausea, Diagnosis, Neurological disorder, Ageing, Global Burden of Disease Study, Health Canada, Calcitonin, Female, Disease, Health insurance, Medical imaging, Aroma compound, Pharmaceutical industry, Ibuprofen, Tylenol, Migraine

However, even in Canada, with a universal health-care system, migraine is underdiagnosed and undertreated.

Key Points: 
  • However, even in Canada, with a universal health-care system, migraine is underdiagnosed and undertreated.
  • Policymakers need to act now to remove the barriers to accessing migraine medications in Canada, particularly as new medications are marketed.

What is migraine?

    • Pain typically affects one side of the head and presents with nausea or vomiting, sensitivity to light or sound and interference with routine physical activity.
    • Migraine can be episodic (fewer than 15 headache days per month) or chronic (15 or more headache days per month for longer than three months).

Impact of migraine

    • Migraine is associated with lost productivity and with other health conditions including asthma, epilepsy and cardiovascular disease.
    • Furthermore, migraine can contribute to mental health problems, including depression and anxiety.
    • Canada is no stranger to this trend, where migraine affects 4.7 per cent of men and 11.8 per cent of women each year.

Historically, migraine has been underdiagnosed

    • Factors influencing diagnosis include an individual’s ability and willingness to access care, and a physician identifying and correctly diagnosing migraine.
    • However, research has demonstrated that for chronic migraine, most individuals report consulting a physician about their headaches.
    • This suggests that in people with chronic migraine specifically, underdiagnosis may be driven by the failure to receive a correct diagnosis from a health-care provider.

Migraine-specific medications are under-used

    • Triptans are among the oldest migraine-specific medications, and the first-line treatment for migraine for those who do not get relief from over-the-counter medications.
    • Despite this, many individuals living with migraine in Canada do not use or have not tried migraine-specific medications.
    • As new migraine-specific medications are approved in Canada, it is important that those who need them can access these treatments.
    • These medications are used to prevent migrainous headaches, and cost over $600 per month.

Steps you can take if you think you might have migraine

    • Migraine Buddy is a migraine tracking app with a questionnaire to help individuals determine if they may have migraine and should discuss their symptoms with a physician.
    • Effective treatment options exist to manage migraine, which can be accessed through a physician.